# Breakthrough Discovery: HELZ2 Protein Offers New Hope for Cholesterol and Fatty Liver Disease Treatment
A novel biological mechanism involving the HELZ2 protein is poised to redefine treatment strategies for cardiovascular disease and fatty liver, according to groundbreaking research conducted at UT Southwestern Medical Center in Texas. Scientists have identified that this protein plays a crucial role in regulating cholesterol levels and fat accumulation in the liver, opening doors to potential therapies that target the root causes of these widespread health concerns.
The examination began with the observation of a mouse exhibiting surprisingly low blood cholesterol alongside an accumulation of fat in its liver. This peculiar finding prompted a team led by zhao Zhang, assistant professor of Center for Host Defense Genetics and Internal Medicine, to delve deeper into the underlying biological processes. Their research,recently published in the journal Circulation,revealed that HELZ2 acts as a central regulator in the release of lipoproteins – the particles responsible for transporting cholesterol and triglycerides from the liver to the bloodstream.
“What we found is that HELZ2 serves as a powerful checkpoint on how many cholesterol-carrying particles end up in the bloodstream,” explained Zhang. The study details how HELZ2 controls the lifespan of the messenger RNA (APOB) essential for producing apoB proteins, the building blocks of these cholesterol-transporting particles.
The system operates with remarkable precision.Increased HELZ2 activity reduces the stability of APOB messenger RNA within liver cells, leading to decreased apoB protein production and, consequently, fewer lipoproteins released into circulation. This process, researchers believe, can limit the buildup of atherosclerosis – the formation of plaques in the arteries.
